Kuan Gandelman

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies
    Kuan Gandelman
    Pfizer Inc, New York, NY 10017, USA
    Am J Ther 19:164-73. 2012
  2. ncbi The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial
    Kuan Gandelman
    Clinical Pharmacology, Pfizer Inc, New York, NY 10017, USA
    J Clin Psychiatry 70:58-62. 2009
  3. ncbi An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia
    Kuan Gandelman
    Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA
    Pediatr Cardiol 32:433-41. 2011
  4. ncbi Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects
    Bimal Malhotra
    Pfizer Inc, New York, NY, USA
    Br J Clin Pharmacol 72:263-9. 2011
  5. ncbi Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine
    Bimal Malhotra
    Pfizer Inc, 685 3rd Avenue, New York, NY 10017, USA
    J Clin Pharmacol 49:477-82. 2009
  6. ncbi Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers
    Bimal Malhotra
    Pfizer Inc, New York, NY, USA
    Br J Clin Pharmacol 72:257-62. 2011
  7. ncbi Pharmacokinetics of an extended release formulation of alprazolam (Xanax XR) in healthy normal adolescent and adult volunteers
    Paul Glue
    Pfizer, Inc, New York, NY 10017, USA
    Am J Ther 13:418-22. 2006
  8. ncbi Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism
    Kuan Gandelman
    Pfizer Inc, 235 East 42nd St, New York, NY 10017, USA
    J Clin Pharmacol 51:229-36. 2011

Detail Information

Publications8

  1. ncbi Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies
    Kuan Gandelman
    Pfizer Inc, New York, NY 10017, USA
    Am J Ther 19:164-73. 2012
    ..These data therefore demonstrate that dosing considerations in the current labels for atorvastatin are similar for Asian compared with Caucasian subjects...
  2. ncbi The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial
    Kuan Gandelman
    Clinical Pharmacology, Pfizer Inc, New York, NY 10017, USA
    J Clin Psychiatry 70:58-62. 2009
    ....
  3. ncbi An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia
    Kuan Gandelman
    Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA
    Pediatr Cardiol 32:433-41. 2011
    ..Atorvastatin also was well tolerated in this population...
  4. ncbi Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects
    Bimal Malhotra
    Pfizer Inc, New York, NY, USA
    Br J Clin Pharmacol 72:263-9. 2011
    ..Currently, no information is available on whether dose adjustment is necessary when fesoterodine is administered with a moderate CYP3A4 inhibitor...
  5. ncbi Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine
    Bimal Malhotra
    Pfizer Inc, 685 3rd Avenue, New York, NY 10017, USA
    J Clin Pharmacol 49:477-82. 2009
    ..43-0.54 ng/mL) is comparable across all groups. In conclusion, because of the involvement of both metabolic and renal elimination pathways, only modest increases in 5-HMT exposures are observed in patients with renal impairment...
  6. ncbi Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers
    Bimal Malhotra
    Pfizer Inc, New York, NY, USA
    Br J Clin Pharmacol 72:257-62. 2011
    ..Preclinical in vitro studies suggest that fesoterodine or 5-hydroxymethyl tolterodine are not likely to affect warfarin metabolism, but a lack of interaction has not been demonstrated in a clinical study...
  7. ncbi Pharmacokinetics of an extended release formulation of alprazolam (Xanax XR) in healthy normal adolescent and adult volunteers
    Paul Glue
    Pfizer, Inc, New York, NY 10017, USA
    Am J Ther 13:418-22. 2006
    ..The most common adverse event was somnolence, which occurred in a dose-related manner. Based on the similar pharmacokinetic profiles, dosing of Xanax XR should be similar in adolescents and adults...
  8. ncbi Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism
    Kuan Gandelman
    Pfizer Inc, 235 East 42nd St, New York, NY 10017, USA
    J Clin Pharmacol 51:229-36. 2011
    ..The clinical significance of the decreased linezolid levels is unclear. Linezolid and rifampin administered alone or in combination was generally safe and well tolerated...